Addiction

ERG sites typically meet or exceed enrollment expectations for Opioid Use Disorder studies.

10

sites with addiction expertise

70

addiction studies

Addiction is a complex disease, often chronic in nature, which affects the functioning of the brain and the body—as well as causing serious damage to families, relationships, schools, workplaces, and neighborhoods. The most common symptoms are severe lack of control, continued use despite serious consequences, failed attempts to quit, tolerance, and withdrawal. Fortunately, continued research is leading to important new therapies that both treat addiction and prevent relapse. ERG addiction experts stand ready to accelerate your programs.

Demonstrated Expertise in Key Indications

  • Alcohol Detoxification
  • Alcohol Relapse prevention
  • Alcohol Use Disorder in Schizophrenia
  • Binge Eating Disorder
  • Cocaine Relapse prevention
  • Nicotine: Smoking cessation
  • Opioid Detoxification
  • Opioid Relapse prevention
  • Opioid Use Disorder
  • Opioid: Use of injectable suboxone

Inpatient and Outpatient Studies Across Phase I-IV Trials

  • Driving simulator studies
  • Early-phase PSG-intensive programs
  • Healthy geriatric sleep studies
  • Jet lag studies
  • Late-phase patient-reported sleep programs
  • Outpatient insomnia
  • Sleep disturbance in Alzheimer’s disease

Industry-Leading Addiction Experts

ERG clinicians are certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) in the use of buprenorphine and have the necessary skills to provide patient counseling. We augment those skills with deep knowledge of the regulatory requirements around working with controlled substances in clinical and research settings, including experience in injection, oral, nasal, infusion, and adhesion delivery systems. Our experts are certified to administer and review a wide range of screening, diagnostic, and assessment scales used in addiction studies. These include: The Addiction Severity Index (ASI), Structured Clinical Interview for DSM-IV (SCID), Modified Mini International Neuropsychiatric Interview Screen (MINI), and DSM V for diagnosis; and the CAGE Questionnaire, Michigan Alcohol Screen Testing (MAST), and Alcohol Use Disorders Identification Test (AUDIT) for screening. Other assessment scales include the Other assessment scales include the Timeline Followback (TLFB), Cocaine Craving Questionnaire (CCQ), Penn Alcohol Craving Scale (PACS), Yale-Brown Obsessive Compulsive Scale (YBOC), Clinical Opiate Withdrawal Scale (COWS), Subjective Opiate Withdrawal Scale (SOWS), Quality of Life Scale (QoL), Symptom Checklist 90 Revised (SCL-90 R), Scales of Psychological Wellbeing (SPWB), Clinical Global Impression (CGI), and Global Assessment of Functioning Scale (GAF).

ERG’s Experienced Addiction Team

Sarah D. Atkinson, MD
Jim Aukstuolis, MD
Robert Billingsley, Jr., MD
Wendy Bond, MD
Gerald Cephas, MD
Bernadette D’Souza, MD
Otto Dueno, MD
Steven Folkerth, MD
Daniel Gruener, MD
George Konis, MD
Shenif Ladak, MD
Hernan Salazar, MD
Stephen Thein, PhD

Affiliate Addiction Team

Evgeny Fink, MD
Paul Miller, MD
Howard Schwartz, MD
Nick Vatakis, MD

ERG expertise spans a wide range of addiction clinical research

Addiction infographic

Targeted Patient Recruitment

With the staggering incidence of patients with substance abuse disorders, ERG has established an unparalleled pipeline of clinical study subjects, continually augmented by physician and patient referrals and robust advertising initiatives. We achieve retention through patient-friendly programs, such as transportation for outpatient visits and smoking rooms for confinement periods.

Spotlight

Doctor icon

Bernadette D’Souza, MD

  • Principal Investigator on 200+ clinical studies
  • Industry-leading expert in psychiatry, neurology, addiction, pain, pediatrics, tobacco
  • Founder of Midwest Clinical Research Center in Dayton, Ohio
Learn More
Doctor icon

Daniel Gruener, MD

  • Conducted 400 early- and late-phase clinical trials
  • Board Certified, American Academy of Pain Management, American Board of Psychiatry and Neurology
  • Industry-leading researcher in psychiatry, pain, addiction, diabetes, and HAL
  • Authored numerous peer-reviewed journal articles and scientific abstracts
Learn More
Pharmaceutical icon

77% of patients remain opioid free

In a multicenter prospective study of postoperative pain management in bunionectomy, patients were able to avoid opioids by combining HTX-011 with an over-the-counter analgesic regimen.

Learn More